Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.47 |
| ▸ | IGF1R | P08069 | 8/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | BMX | P51813 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602499 | 0.85 | IGF1R (0.51) | AURKAIGF1RMAPK8LCKJAK3 | |
| SCHEMBL4623410 | 0.74 | MAPT (0.46) | AURKAIGF1RJAK3JAK2EGFR | |
| SCHEMBL3602100 | 0.73 | AURKA (0.51) | AURKAIGF1RMAPK8AURKBLCK | |
| SCHEMBL3300933 | 0.73 | AURKA (0.80) | AURKAMAPK8AURKB | |
| SCHEMBL3596730 | 0.72 | IGF1R (0.49) | AURKAIGF1RLCKJAK3JAK2 | |
| SCHEMBL3302571 | 0.71 | AURKA (0.51) | AURKAIGF1RMAPK8AURKBLCK | |
| SCHEMBL14096598 | 0.71 | HTR2A (0.47) | — | |
| SCHEMBL4622912 | 0.71 | JAK2 (0.45) | IGF1RJAK3JAK2EGFR | |
| SCHEMBL3303484 | 0.70 | AURKA (0.64) | AURKAMAPK8AURKB | |
| SCHEMBL27786687 | 0.70 | DHFR (0.46) | AURKAIGF1RMAPK8AURKBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| EP-2104673-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | claimed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | claimed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2104673-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008099072-A2 | NEW 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035907-A1 | NEW 2,4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF ESSENTIALLY AS IKK INHIBITORS | IKBKB, CDK2, IKBKE | AURKA 494/4885IGF1R 1100/4885MAPK8 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.